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a  b  s  t  r  a  c  t
Since  implementation  of  infant  immunization  with  7-valent  pneumococcal  conjugate  vaccine  (PCV7),
increased  rates  of  pneumococcal  pneumonia  have  been  reported  among  adults.  Using  a  cohort  of
mother–infant  pairs identiﬁed  from  the  General  Practice  Research  Database  in the  UK  we  found  that
from  2006  to  2010  the  annual  incidence  rate  of  pneumococcal  pneumonia  among  mothers  increased
from  61/100,000  to  81/100,000.  We  identiﬁed  43 cases  of  pneumococcal  pneumonia  in mothers  and  430
control mother–infant  pairs.  The  conditional  odds  ratio  of  pneumococcal  pneumonia  in mothers  whose






two doses  was  4.0  (95%  conﬁdence  interval  [95%CI]:  1.0–15.8),  and  11.0  (95%CI:  1.2–98.6)  when  compared
with  mothers  whose  infants  received  no  vaccinations.  The  incidence  of pneumococcal  pneumonia  may
have increased  in  mothers  following  the  introduction  of  PCV7,  possibly  because  mothers  whose  infants
received  PCV7  are  at increased  risk  for  pneumococcal  pneumonia.  Though  there  is a chance  of  bias  inher-
ent to  observational  studies,  the  study  ﬁndings  support  close  monitoring  of adult  pneumococcal  disease
and potential  role  of  adult vaccination  needs  to be  explored.. Introduction
Seven-valent pneumococcal conjugate vaccine (PCV7) was
dded to the United Kingdom (UK) infant immunization schedule
n September 2006 as a three-dose series to be administered at 2,
, and 13 months and offers protection against the most common
erotypes accounting for invasive pneumococcal diseases (IPD) in
hildren [1].  Following the success in the United States (US), in the
K the risk of vaccine serotype pneumococcal carriage and IPD in
nfants declined as well as in adults who are unvaccinated [2–5].
The dramatic reduction in IPD caused by PCV7 serotypes in
he UK has coincided with an increase in pneumococcal infections
ttributable to non-PCV7 serotypes [6].  This increase has earlier
een noted in North America [7] and has thus far been insufﬁcient
o offset the total reduced incidence of PCV7-serotype pneumo-
occal disease [1].  However, in a few recent studies from Europe,
t appears that the overall rates of asymptomatic nasopharyngeal
arriage of non-PCV7 serotypes may  be increasing among adults.
n a randomized controlled trial from The Netherlands, parents
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experienced a two-fold increase in nasopharyngeal carriage of non-
PCV7 serotypes if their infants were fully vaccinated compared
with control parents whose infants were not vaccinated, and a 29%
increase in overall pneumococcal carriage [8].  In a study comparing
serotype-speciﬁc carriage in children and parents before and after
introduction of PCV7 in the UK, Flasche et al. similarly observed a
ﬁve-fold increase of non-vaccine serotype carriage among parents
and a 28% increase in overall carriage [9].  Neither the UK or the
Netherlands have detected a corresponding increased risk of over-
all IPD among adults via national surveillance networks [9,10].  In
the US, however, Metlay et al. were the ﬁrst to observe a statistically
signiﬁcant 7% annual increase in community-acquired pneumo-
coccal bacteremia among hospitalized adult patients from 2002
to 2008, particularly in young adults, and predominantly caused
by increases in non-PCV7 pneumococcal disease [11]. Another
study conducted in the UK found a statistically signiﬁcant dou-
bling in overall IPD incidence from 2002 to 2009 among adults aged
15–64 years despite nearly complete uptake of PCV7 vaccine among
infants [12].
We therefore carried out a study to assess the incidence rates
of lobar/pneumococcal pneumonia following the introduction of
PCV7 in the UK in mothers of infants who are generally at highest
risk for transmission of the pneumococcal bacteria from their young
child. We  also assessed a mother’s risk of developing pneumococcal
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. Methods
.1. Data source and setting
This study was conducted using data from the GPRD, which is
dministered by the Medicines and Healthcare Products Regula-
ory Agency and has been previously described in detail [13–15].  In
rief, the GPRD contains electronic medical records for a nation-
lly representative group of British residents currently enrolled
n more than 450 general practice ofﬁces in the UK. General
ractitioners are trained to accurately record information about
atient demographics, medical diagnoses and procedures that are
art of routine care or resulting from hospitalizations, results of
aboratory testing, and referrals to hospitals using READ codes,
hich are standard clinical codes – akin to ICD-9 codes – used
n general practice in the United Kingdom. READ codes support
etailed clinical encoding of multiple patient phenomena including
emographic (sex, race/ethnicity, religion, occupation, other social
ircumstances) and clinical information (medical diagnoses, clini-
al signs, symptoms and observations, laboratory tests and results,
iagnostic, therapeutic or surgical procedures performed). In addi-
ion, the GPRD includes detailed information about prescriptions
nd vaccinations. The quality and completeness of the informa-
ion recorded in the GPRD has been widely validated [13–15].  The
atabase captures nearly all episodes of pneumonia that are diag-
osed and treated by general practitioners, require hospitalization,
r result in death [16]. Also, infant immunizations are adminis-
ered in general practices, and patient records describing receipt of
mmunizations have been found to be virtually complete [17–20].
his study was approved by the Independent Scientiﬁc Advisory
ommittee (ISAC) within the UK Medicines and Healthcare Prod-
cts Regulatory Agency.
.2. Study population and identiﬁcation of lobar/pneumococcal
neumonia
The study comprised two analyses. In the ﬁrst we estimated
nnual incidence rates of ﬁrst-time lobar/pneumococcal pneumo-
ia using the GPRD to identify a study population of all mothers
ged 20 through 39 years who gave birth to their ﬁrst child on
r after January 1, 2005 and who were present in the GPRD at
ny time from 2006 through 2010. We  linked mothers to their
rst-born child using a unique identiﬁcation number given to
embers of the same family and the date of delivery code in the
other’s record in combination with the date of birth in her child’s
ecord.
Among the study population, we identiﬁed mothers who
ad a record of a ﬁrst-time diagnosis of community-acquired
obar/pneumococcal pneumonia between 2006 and 2010 using the
peciﬁc GPRD READ code H21.00 (this code is consistent with ICD-9
ode 481). Annual incidence rates of ﬁrst-time lobar/pneumococcal
neumonia in mothers were estimated by dividing the num-
er of incident cases that occurred during each year of the
tudy period by the total amount of person-time contributed
y mothers in the study population during the same study
ear.
.3. PCV7 coverage among ﬁrst-born infants
Annual PCV7 coverage was estimated as the proportion of ﬁrst-
orn children who received one, two, or three doses of PCV7
y 24 months of age for each year of the study period. Esti-
ates of annual vaccine coverage were restricted to ﬁrst-born
hildren who were present in the database during each study
ear.(2013) 1590– 1596 1591
2.4. Case–control analysis
In the case–control analysis, a subset of all eligible case moth-
ers with a ﬁrst-time diagnosis of lobar/pneumococcal pneumonia
was  included if these cases had at least two  years of com-
plete medical history, including complete information on smoking
status, comorbidities and drug prescriptions, recorded in the
database prior to their diagnosis. This was done to ensure adequate
clinical information on potential risk factors that may  be con-
founders of the association between infant PCV7 vaccination and
lobar/pneumococcal pneumonia. The cut-off for two  years of his-
tory is a commonly used period for primary care database research
to select “active” patients. In order to conﬁrm the diagnosis of
lobar/pneumococcal pneumonia, all electronic medical records of
the cases were reviewed for information on whether the diagnosis
occurred in the hospital or in primary care, and for details of treat-
ment and high-risk comorbidities. In addition, because asthma is a
frequent risk factor for pneumonia, we wanted to make sure that
the incident cases of pneumonia were not a complication of exist-
ing asthmatic disease. Medical record review indicated that only
one case occurred as a complication of existing asthma while all
other cases appeared to be new disease. The date of the ﬁrst-time
diagnosis was  considered the index date.
Ten control mothers without a history of any pneumonia and
who  had at least two years of complete medical history in the
database were randomly selected from the same study popula-
tion as the cases and matched to each case on index date of the
case diagnosis, age, birth date of ﬁrst child, current smoking sta-
tus and presence or absence of chronic lung disease [20], as well as
use of any benzodiazepine or anti-depressant medications [21]. We
chose to match controls to cases on prior use of benzodiazepines
or anti-depressants because more than half the cases in our study
had been prescribed at least one of these medications, and because
there is some evidence that the treated conditions may  confer
increased risk of pneumonia or may  be a marker for health care con-
sumption [21]. Smoking status was classiﬁed as current, former, or
non-smoker based on GPRD codes recorded prior to the index date.
2.5. Exposure to infant PCV7 vaccination
Mothers were classiﬁed as being exposed or unexposed based
on the PVC7 immunization status of their ﬁrst-born infant. Based
on the recommended immunization schedule, mothers whose ﬁrst-
born infants received three doses of PCV7 were considered exposed,
and mothers who received fewer than three doses of PCV7 were
considered not exposed [1,20].  PCV7 vaccination status in infants
was  ascertained using the following READ codes recorded in the
GPRD: 657L.00, 657M.00, 657N.00, 6572.00, 6572000 or 900.00.
Only vaccinations administered at least 14 days prior to the index
date of the mother were considered.
2.6. Statistical analyses
Conditional logistic regression was used to estimate odds ratios
and associated 95% conﬁdence intervals (CI) describing the asso-
ciation between infant PCV7 vaccination and lobar/pneumococcal
pneumonia in the mother after adjustments for the matched covari-
ates using SAS, Version 9.1 (SAS Institute, Inc., Cary, NC). Mothers
whose infants received at least three doses of PCV7 were compared
to (1) mothers whose infants received zero, one or two  doses and to
(2) mothers whose infants received zero doses. Because of concern
that residual confounding may  have been present for certain covari-
ates and because we  were restrained by the number of cases and
controls, we a priori deﬁned a few subgroups for restricted analyses






























Characteristics of mothers with lobar/pneumococcal pneumonia (cases) and
matched controls on the index date.
Characteristic N (%)
Cases (n = 43) Controls (n = 430)
Mean age of mother in years (SD) 31 (5) 31 (5)
Child’s age at index date
36 months or less 29 (67) 294 (68)
More than 36 months 14 (33) 136 (32)
Smoking status:a
Current smoker 13 (30) 130 (30)
Non-smoker 17 (40) 170 (40)
Former smoker 13 (30) 130 (30)
Current chronic pulmonary disease 11 (26) 110 (26)
Any antidepressants or
benzodiazepines prescribed
26 (60) 260 (60)
Presence of other infants in the
householdb
23 (53) 245 (56)ig. 1. Annual age-speciﬁc incidence rates of ﬁrst-time lobar/pneumococcal pneu-
onia per 100,000 person-years among mothers aged 20 through 39 years from
006 through 2010 (N = 187,137 total person-years).
ncluding the mother’s age, number of children in the household,
bsence of asthma, time period, and duration of exposure interval.
. Results
In all, 115 cases of ﬁrst-time lobar/pneumococcal pneumonia
ere recorded among mothers aged 20 through 39 years. Moth-
rs contributed a total of 187,137 person-years during the total
tudy period. There were no cases of ﬁrst-time lobar/pneumococcal
neumonia in 20–24 year olds in 2006 and only one in 2007. The
umber increased to three cases in 2009 and two  in 2010. There
ere more cases in the older ages with incidence rates increasing
rom 33 per 100,000 in ages 20–24 to 104 per 100,000 in the 35–39
ears age-group in 2010. The overall rates in all mothers increased
rom 61/100,000 in 2006 to 81/100,000 in 2010 (Fig. 1).
Among a total of 232,998 twenty-four month-old ﬁrst-born
nfants in the linked mother–infant database, the number of infants
ho contributed to the analysis ranged from 43,993 to 48,468 per
tudy year. In this population the uptake of ﬁrst PCV7 vaccine
anged from 7150 infants in 2006 (15%) to 38,414 infants (88%) in
010 (Fig. 2). Corresponding ﬁgures for a second and third vaccine
ptake were 325 (<1%) and 92 (<1%) in 2006, and 36,824 (84%) and
8,752 (65%) in 2010, respectively.
A total of 43 mothers with a diagnosis of incident
obar/pneumococcal pneumonia met  the criteria for the
ase–control analysis. Among these, 12 (28%) cases had uncom-
licated pneumonia and were treated with antibiotics in primary
are and 29 (63%) cases had pneumonia requiring hospitalization.
ig. 2. Uptake (%) of one, two or three doses of PCV7 among infants at 24 months
f  age according to calendar year from 2006 to 2010.a Smoking status was known for all cases and used to match controls.
b We  did not match on this factor.
In two  cases recorded with lobar/pneumococcal pneumonia
who were treated in primary care, their type of treatment was
unclear from their medical records. The mean age of cases was
31 years (±5 years), 30% were current smokers, 26% had chronic
pulmonary disease, and 60% had ever received a benzodiazepine or
anti-depressant prescription prior to the index date (Table 1). The
43 case mothers were matched to 430 control mothers with no
diagnosis of pneumonia. Demographic and clinical characteristics
of cases and controls are provided in Table 1.
The conditional odds ratio of lobar/pneumococcal pneumonia
in mothers whose ﬁrst infant received three doses of PCV7 com-
pared to mothers whose infants received zero, one, or two doses
of PCV7 was  4.0 (95%CI: 1.0–15.8). The odds ratio increased to
11.0 (95%CI: 1.2–98.6) when mothers whose infants received three
doses of PCV7 were compared with mothers whose infants did
not receive any PCV7 vaccinations. The odds ratios for mothers
whose ﬁrst-born infant received three doses of PCV7 compared to
mothers whose infants received zero, one, or two doses of PCV7
vaccinations for the development of lobar/pneumococcal pneumo-
nia ranged from 3.3 to 8.2 in analyses restricted to young women,
those with no asthma, short exposure interval, and those in later
study years (Table 2).
4. Discussion
This study showed that the incidence of ﬁrst-time
lobar/pneumococcal pneumonia in mothers has increased since
the introduction of PCV7 infant immunization in the UK.  We  also
observed that among infants, one in three age-eligible infants
had not completed the recommended three-dose series by the
age of 24 months in 2010. Finally, results from our case–control
analysis indicated that there was  an association between the
risk of lobar/pneumococcal pneumonia in mothers and the PCV7
immunization status of her ﬁrst-born infant. This association was
highest when comparing the odds of disease among mothers
whose infants received three doses of PCV7 to mothers whose
infants did not receive any doses, and were not meaningfully
attenuated when we restricted the analysis to relevant subgroups.
Although we did not have serotype-speciﬁc data, these results
are consistent with the notion that the net indirect beneﬁts of
the PCV7 immunization program due to decreased circulation of
PCV7-serotype pneumococci in adults are likely offset by the coin-
ciding clonal expansion of non-PCV7 serotypes [6–9,11,23].  These
non-PCV7 serotypes may  be more prevalent in adults or more inva-
sive, thereby increasing the likelihood of disease. For example,
Flasche et al. observed a high case-to-carrier ratio, a measure of
E. Hak et al. / Vaccine 31 
Table 2
Conditional odds ratios for the association between PCV7a vaccination status of
ﬁrst-born infants and lobar/pneumococcal pneumonia among mothers overall, and
across strata.
Stratum N (%) ORb (95%CI)
Cases (n = 43) Controls (n = 430)
Full population
<3 doses of PCV7 21 (49%) 252 (59) Reference
3  doses of PCV7 22 (51%) 178 (41) 4.0 (1.0–15.8)†
Mothers <30 years
<3 doses of PCV7 10 (59) 113 (71) Reference
3  doses of PCV7 7 (41) 46 (29) 7.2 (0.5–96.3)
Mothers without asthma
<3 doses of PCV7 17 (53) 200 (63) Reference
3  doses of PCV7 15 (47) 120 (37) 3.3 (0.7–13.9)
Mothers with exposure time of less than 36 months since birth of ﬁrst infant
<3  doses of PCV7 12 (41) 165 (56) Reference
3  doses of PCV7 17 (59) 129 (44) 8.5 (1.1–70.3)‡
Mothers with index dates in 2009 and 2010
<3  doses of PCV7 9 (33) 117 (43) Reference
3  doses of PCV7 18 (67) 153 (57) 3.6 (0.7–20.2)
a 7-Valent pneumococcal conjugate vaccine.
b Controls were matched to cases on index date, date of birth, age, presence of








































associated with increased risk for pneumonia and high health care† p-value 0.05.
‡ p-value 0.02; all other p-values >0.05.
neumococcal invasiveness, for the most prevalent non-PCV7
erotypes 19A, 7F and 22F several years after PCV7 implementation
n the UK, and found that serotypes 7F and 22F were also highly
revalent in adults [9].  Non-PCV7 serotypes 8 and 12F that were
ot otherwise found in carriers also commonly occurred among
dult IPD cases. Whether the net effect of this shift is a decrease
r increase of pneumococcal disease depends on acquired immu-
ity against PCV7-serotype and non-PCV7 serotypes. For infants,
oung children and the elderly, the net effect is positive, despite
eplacement disease by e.g. 19A. For adults this may  be different
ecause of already low incidence of pneumococcal disease. In a
tudy from the Netherlands among adults with IPD, intermediate
o high fatality rates were observed among adults with IPD due to
erotypes 19A (19% fatality rate), 7F (10%), 12F (12%), 8 (15%) and
2F (18%); and together, these serotypes were present in more than
 quarter of adult IPD patients [24]. Except for 7F and 19A, these
on-PCV7 serotypes are not covered by the current successors of
CV7, i.e. PCV10 and PCV13, and the future epidemiology of these
neumococcal serotypes among adults remains uncertain.
The observed increased incidence rates of lobar/pneumococcal
neumonia among mothers are consistent with another US study
10]. In the Netherlands, a comparable annual increase in the rate of
PD was noted among persons aged 5–49 two years post-PCV7 vac-
ination, though this increase was not statistically signiﬁcant [10].
lston and colleagues also detected increases in pneumonia hospi-
alizations among 18–64 year-old British adults in whom incidence
ncreased from 70 per 100,000 population in 2006 to 84 per 100,000
n 2009 (data provided on request by Dr. J. W.T. Elston).
During the study period, we observed that the rate of uptake of
 ﬁrst dose of PCV7 vaccine among 24 month-old ﬁrst-born infants
as slightly lower than that reported by the National Health Service
NHS) (91% versus 88% in our study in 2009–2010), and that the NHS
eported a substantially higher rate of the booster dose of PCV7 than
as found in our study (88% versus 68% in our study in 2009–2010)
25]. However, the NHS deﬁnes a booster dose of PCV7 as receipt
f one dose on or after 12 months of age, irrespective of the num-
er of doses before that age, and before a child’s second birthday.
fter reviewing 50 infant medical records randomly selected from
he control mother–infant pairs, we found that approximately one
hird of control infants received a booster dose after 12 months, but(2013) 1590– 1596 1593
had only received one PCV7 vaccination before 12 months of age.
According to the current immunization recommendations, but in
contrast to the deﬁnition used by the NHS, these infants were not
classiﬁed as being fully vaccinated in our study.
Despite several strengths of our study including identiﬁca-
tion of a large cohort of unique mother–infant pairs and use of
highly accurate clinical information, our study has potential lim-
itations inherent to the conduct of observational studies. First,
exclusive use of READ codes used in the GPRD to ascertain cases
of lobar/pneumococcal pneumonia created potential for misclas-
siﬁcation of the outcome diagnosis [21,22].  Twenty-nine cases
of lobar/pneumococcal pneumonia required hospitalization, and
standard diagnostic tests were used to conﬁrm the presence of
the pneumococcal bacteria. The remaining 14 cases were treated
in primary care and did not have records conﬁrming the presence
of pneumococcal bacteria. We  suspect that pneumococcal etiology
for these cases was  most likely conﬁrmed by rapid urinary tests
or by examination of X-rays, though this information is lacking in
the medical records. We  recently demonstrated in a meta-analysis
that in the United Kingdom based on 5 cohort studies that more
than 30% of all community-acquired pneumonia cases were caused
by Streptococcus pneumonia (Rozenbaum et al., European Journal
of Clinical Microbiology & Infectious Diseases, accepted for publica-
tion). It is therefore likely that the majority of lobar (pneumococcal)
cases were caused by S. pneumonia. Restriction of the analysis to
conﬁrmed hospitalized cases and controls showed similar asso-
ciations (OR 3.2, 95% conﬁdence interval 0.75–13.7) with largely
overlapping conﬁdence intervals when comparing mothers of chil-
dren who received three versus 2, 1, or 0 PCV7 doses. In addition, we
cannot exclude the possibility that some cases had a prior episode of
pneumococcal pneumonia before our study started in 2006. How-
ever, it is unlikely that this would have strongly affected our results
given the relatively low risk for pneumococcal pneumonia in this
population.
Second, we may  have underestimated the prevalence of infant
PCV7 vaccination, for example, if infants received a vaccine dose
from a physician other than their own GP  who may not have
recorded their vaccine in the GPRD database. Importantly, since
GPs are paid a small fee for each immunization that they adminis-
ter, child immunization records in the UK are expected to be highly
accurate [20]. Because vaccinations are given in primary care which
is accessible to everyone, under-ascertainment of PCV7 immuniza-
tions would likely be random, and therefore expected to result in a
bias toward the null.
Third, a booster dose might not be necessary to obtain immunity
and classifying children with one or two  received PCV7-doses in
the reference group may  have led to underestimations. We  there-
fore decided to add a subgroup analysis including only mothers
whose children received none of the vaccination versus those who
received 3 doses and risks increased (OR 4.6, 95% 0.82–25.6, 29
cases and 269 controls).
Fourth, the presence of other children in the household may
have confounded our results. We  determined the number of cases
and controls who had more than one child in the household during
the study period, and found that cases and controls did not differ
in these proportions.
Fifth, our results may  be susceptible to residual confounding by
health behaviors that may  differ between cases and controls. We
opted to use matching to control for receipt of prescriptions for
antidepressants or benzodiazepines as a proxy for health behav-
iors because depression and sleeping problems appeared common
among cases, and because such psychological diseases have beenconsumption [22]. While this may  have reduced some of the differ-
ence between cases and controls, other factors like hand hygiene
or practicing other preventive or risk taking behaviors could not
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e controlled for in our analysis. However, it seems reasonable to
ssume that preventive behaviors would be more common among
others whose infants received all recommended vaccinations,
hich would have again resulted in a bias toward the null. In addi-
ion, due to the magnitude of our observed associations, we do not
elieve that our results are fully attributable to residual confound-
ng, especially not because other risk elevating conditions than lung
isease and depression were not present in the medical records.
Finally, the observed increased trend in pneumococcal pneumo-
ia might be due to diagnostic bias. However, a recent publication
sing data from the GPRD demonstrated that the incidence of
neumoconiosis, which has similar diagnosing patterns as pneu-
ococcal disease, decreased from 2005 to 2008, suggesting that
iagnostic bias is unlikely [26].
Despite these limitations, this study suggests that
obar/pneumococcal pneumonia is increasing among young
others in close contact with infants, and that infant PCV7 immu-
ization may  be associated with a higher risk of pneumococcal
neumonia in mothers. Because our ﬁndings indicate potential
ncreases in risk of pneumonia after PCV7 vaccination, studies
re now warranted to monitor the impact of large-scale pneu-
ococcal vaccination, including the impact of increased valency
neumococcal vaccines, on adults worldwide.
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379.00 ex moderate smoker
37K.00 stopped smoking
nknown(2013) 1590– 1596
None of these codes present
Ever asthma or COPD (any of these codes before index date)
173A.00 EXERCISE INDUCED ASTHMA
663..11 ASTHMA MONITORING
663N.00 ASTHMA DISTURBING SLEEP
663N000 ASTHMA CAUSING NIGHT WAKING
663N100 ASTHMA DISTURBS SLEEP WEEKLY
663N200 ASTHMA DISTURBS SLEEP FREQUENTLY
663O.00 ASTHMA NOT DISTURBING SLEEP
663O000 ASTHMA NEVER DISTURBS SLEEP
663P.00 ASTHMA LIMITING ACTIVITIES
663Q.00 ASTHMA NOT LIMITING ACTIVITIES






663W.00 ASTHMA PROPHYLACTIC MEDICATION USED
663d.00 EMERGENCY ASTHMA ADMISSION SINCE LAST APPOINTMENT
663e.00 ASTHMA RESTRICTS EXERCISE
663e000 ASTHMA SOMETIMES RESTRICTS EXERCISE
663e100 ASTHMA SEVERELY RESTRICTS EXERCISE
663f.00 ASTHMA NEVER RESTRICTS EXERCISE
663h.00 ASTHMA – CURRENTLY DORMANT
663j.00 ASTHMA – CURRENTLY ACTIVE
66YJ.00 asthma follow-up
66YK.00 asthma monitoring
66YE.00 asthma follow up
8793.00 ASTHMA CONTROL STEP 0
8794.00 ASTHMA CONTROL STEP 1
8795.00 ASTHMA CONTROL STEP 2
8796.00 ASTHMA CONTROL STEP 3
8797.00 ASTHMA CONTROL STEP 4
8798.00 ASTHMA CONTROL STEP 5
8H2P.00 EMERGENCY ADMISSION, ASTHMA
9OJ1.00 ATTENDS ASTHMA MONITORING
9OJ2.00 REFUSES ASTHMA MONITORING
9OJ3.00 ASTHMA MONITOR OFFER DEFAULT
9OJ4.00 ASTHMA MONITOR 1ST LETTER
9OJ5.00 ASTHMA MONITOR 2ND LETTER
9OJ6.00 ASTHMA MONITOR 3RD LETTER
9OJ7.00 ASTHMA MONITOR VERBAL INVITE
9OJ8.00 ASTHMA MONITOR PHONE INVITE
9OJ9.00 ASTHMA MONITORING DELETED
9OJA.00 ASTHMA MONITORING CHECK DONE
9OJA.11 ASTHMA MONITORED
9OJZ.00 ASTHMA MONITORING ADMIN.NOS
9Q21.00 PATIENT IN ASTHMA STUDY
H33..00 ASTHMA
H33..11 BRONCHIAL ASTHMA
H330.00 EXTRINSIC (ATOPIC) ASTHMA
H330.11 ALLERGIC ASTHMA
H330.12 CHILDHOOD ASTHMA
H330.13 HAY FEVER WITH ASTHMA
H330.14 POLLEN ASTHMA
H330000 EXTRINSIC ASTHMA WITHOUT STATUS ASTHMATICUS
H330011 HAY FEVER WITH ASTHMA
H330100 EXTRINSIC ASTHMA WITH STATUS ASTHMATICUS
H330111 EXTRINSIC ASTHMA WITH ASTHMA ATTACK
H330z00 EXTRINSIC ASTHMA NOS
H331.00 INTRINSIC ASTHMA
H331.11 LATE ONSET ASTHMA
H331000 INTRINSIC ASTHMA WITHOUT STATUS ASTHMATICUS
H331100 INTRINSIC ASTHMA WITH STATUS ASTHMATICUS
H331111 INTRINSIC ASTHMA WITH ASTHMA ATTACK
H331z00 INTRINSIC ASTHMA NOS
H332.00 MIXED ASTHMA
H333.00 ACUTE EXACERBATION OF ASTHMA
H33z.00 ASTHMA UNSPECIFIED
H33z000 STATUS ASTHMATICUS NOS
H33z011 SEVERE ASTHMA ATTACK
H33z100 ASTHMA ATTACK
H33z111 ASTHMA ATTACK NOS
H33z200 LATE-ONSET ASTHMA
H33zz00 ASTHMA NOS
H33zz11 EXERCISE INDUCED ASTHMA
H33zz12 ALLERGIC ASTHMA NEC
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35y700 WOOD ASTHMA
47y000 DETERGENT ASTHMA
30.12 RECURRENT WHEEZY BRONCHITIS
302.00 WHEEZY BRONCHITIS
312000 CHRONIC ASTHMATIC BRONCHITIS
312011 CHRONIC WHEEZY BRONCHITIS
791.00 Further asthma – drug prevent. 11
JF7300 Adverse reaction to theophylline (asthma) 53
JF7.00 Adverse reaction to antiasthmatics 2
JF7z00 Adverse reaction to antiasthmatic NOS 1
60F615 [X] Adverse reaction to theophylline asthma 3
4B4.00 H/O: ASTHMA
3...00 Chronic obstructive pulmonary disease
3...11 Chronic obstructive airways disease
36..00 Mild chronic obstructive pulmonary disease
37..00 Moderate chronic obstructive pulmonary disease
38..00 Severe chronic obstructive pulmonary disease
39..00 Very severe chronic obstructive pulmonary disease
3y..00 Other speciﬁed chronic obstructive airways disease
3y..11 Other speciﬁed chronic obstructive pulmonary disease
3z..00 Chronic obstructive airways disease NOS
3z..11 Chronic obstructive pulmonary disease NOS
yu3100 [X]Other speciﬁed chronic obstructive pulmonary disease
312100 Emphysematous bronchitis
312.00 Obstructive chronic bronchitis
312z00 Obstructive chronic bronchitis NOS
312200 Acute exacerbation of chronic obstructive airways disease
nti-depressant use or benzodiazepine use (past two years, code
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